OTCPK:CURL.F

Stock Analysis Report

Executive Summary

Curaleaf Holdings, Inc. operates as an integrated medical and wellness cannabis operator in the United States.

Snowflake

Fundamentals

High growth potential with excellent balance sheet.

Risks

  • Curaleaf Holdings has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Curaleaf Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.8%

OTCPK:CURL.F

-1.6%

US Pharmaceuticals

-1.9%

US Market


1 Year Return

n/a

OTCPK:CURL.F

-8.5%

US Pharmaceuticals

-3.3%

US Market

No trading data on CURL.F.

No trading data on CURL.F.


Share holder returns

CURL.FIndustryMarket
7 Day-3.8%-1.6%-1.9%
30 Day-18.3%-4.5%-6.2%
90 Day-32.7%-5.5%0.3%
1 Yearn/a-6.3%-8.5%-1.1%-3.3%
3 Yearn/a8.4%1.0%37.9%28.9%
5 Yearn/a20.1%7.5%50.8%34.1%

Price Volatility Vs. Market

How volatile is Curaleaf Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Curaleaf Holdings undervalued based on future cash flows and its price relative to the stock market?

6.81x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Curaleaf Holdings to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Curaleaf Holdings to establish if it is available at substantial discount.


Price Based on Earnings

Curaleaf Holdings is loss making, we can't compare its value to the US Pharmaceuticals industry average.

Curaleaf Holdings is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Curaleaf Holdings, we can't assess if its growth is good value.


Price Based on Value of Assets

Curaleaf Holdings is overvalued based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Curaleaf Holdings expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

146.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Curaleaf Holdings's revenue is expected to grow significantly at over 20% yearly.

Curaleaf Holdings's earnings are expected to grow significantly at over 20% yearly.

Curaleaf Holdings's revenue growth is expected to exceed the United States of America market average.

Curaleaf Holdings's earnings growth is expected to exceed the United States of America market average.

Curaleaf Holdings's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Curaleaf Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Curaleaf Holdings performed over the past 5 years?

-1892.3%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Curaleaf Holdings does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Curaleaf Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Curaleaf Holdings's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Curaleaf Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Curaleaf Holdings has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Curaleaf Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Curaleaf Holdings's financial position?


Financial Position Analysis

Curaleaf Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Curaleaf Holdings's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Curaleaf Holdings's level of debt (20.1%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Curaleaf Holdings's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2.7x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Curaleaf Holdings has sufficient cash runway for 1.7 years based on current free cash flow.

Curaleaf Holdings has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 95.6% each year.


Next Steps

Dividend

What is Curaleaf Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Curaleaf Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Curaleaf Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Curaleaf Holdings has not reported any payouts.

Unable to verify if Curaleaf Holdings's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Curaleaf Holdings has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Curaleaf Holdings's salary, the management and board of directors tenure and is there insider trading?

0.6yrs

Average management tenure


CEO

Joseph Lusardi (44yo)

3.4yrs

Tenure

0

Mr. Joseph Lusardi serves as Director of Curaleaf Holdings, Inc. since March 2016 and serves as its President. Mr. Lusardi has been Chief Executive Officer of Curaleaf Holdings, Inc. since March 2016. Mr.  ...


Management Age and Tenure

0.6yrs

Average Tenure

52yo

Average Age

The average tenure for the Curaleaf Holdings management team is less than 2 years, this suggests a new team.


Board Age and Tenure

0.8yrs

Average Tenure

58yo

Average Age

The average tenure for the Curaleaf Holdings board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by Curaleaf Holdings individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$14,066,23801 Aug 19
Boris Jordan
EntityIndividual
Role
Chairman of the Board
Executive Chairman
Shares1,900,843
Max PriceUS$7.40
SellUS$14,066,23801 Aug 19
Bellmawr Investors, LLC
EntityCompany
Shares1,900,843
Max PriceUS$7.40
BuyUS$4,71712 Dec 18
Peter Derby
EntityIndividual
Role
Member of the Board of Directors
Director
Shares1,000
Max PriceUS$4.72

Ownership Breakdown


Management Team

  • Boris Jordan (53yo)

    Executive Chairman

    • Tenure: 0.0yrs
  • Dan Foley

    Vice President of Finance & Investor Relations

    • Tenure: 0.0yrs
  • Todd Goffman

    General Counsel & Secretary

    • Tenure: 0.6yrs
  • Neil Davidson (47yo)

    Chief Financial Officer

    • Tenure: 0.6yrs
  • Stuart Wilcox (58yo)

    Chief Operating Officer

    • Tenure: 2.0yrs
  • Joseph Lusardi (44yo)

    President

    • Tenure: 3.4yrs
  • Jon Faucher (41yo)

    Executive Vice President of Finance

    • Tenure: 0.6yrs
  • Carolyn Fedigan (55yo)

    Senior Vice President of Human Resources

    • Tenure: 0.0yrs
  • Katrina Yolen (52yo)

    Senior Vice President of Marketing

    • Tenure: 0.0yrs
  • Troy Morgan

    Senior Vice President of Compliance

    • Tenure: 0.2yrs

Board Members

  • Boris Jordan (53yo)

    Executive Chairman

    • Tenure: 0.0yrs
  • Peter Derby (58yo)

    Director

    • Tenure: 0.8yrs
  • Karl Johansson (69yo)

    Director

    • Tenure: 0.8yrs
  • Steven Patierno (61yo)

    Chairman of the Medical Advisory Board & Director

    • Tenure: 0.0yrs
  • David Casarett

    Member of the Medical Advisory Board

    • Tenure: 0.0yrs
  • Joseph Lusardi (44yo)

    President

    • Tenure: 3.4yrs
  • Robert Schnoll

    Member of the Medical Advisory Board

    • Tenure: 0.0yrs
  • Brian Thomas

    Member of the Medical Advisory Board

    • Tenure: 0.0yrs

Company Information

Curaleaf Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Curaleaf Holdings, Inc.
  • Ticker: CURL.F
  • Exchange: OTCPK
  • Founded: 2010
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$4.057b
  • Listing Market Cap: CA$3.050b
  • Shares outstanding: 475.02m
  • Website: https://www.curaleaf.com

Location

  • Curaleaf Holdings, Inc.
  • 301 Edgewater Place
  • Suite 405
  • Wakefield
  • Massachusetts
  • 1880
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CURACNSX (Canadian National Stock Exchange)YesSubordinated Voting SharesCACADOct 2018
CURL.FOTCPK (Pink Sheets LLC)YesSubordinated Voting SharesUSUSDOct 2018

Biography

Curaleaf Holdings, Inc. operates as an integrated medical and wellness cannabis operator in the United States. It cultivates, processes, markets, and/or dispenses a range of cannabis products, such as vape ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/26 01:16
End of Day Share Price2019/08/23 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.